These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35190110)

  • 1. Tumor Lysis Syndrome.
    Barbar T; Jaffer Sathick I
    Adv Chronic Kidney Dis; 2021 Sep; 28(5):438-446.e1. PubMed ID: 35190110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome: a systematic review of case series and case reports.
    Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J
    Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasburicase in cancer-related hyperuricemia.
    Rodriguez M; Campara M; Haaf C
    Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour lysis syndrome.
    Calvo Villas JM
    Med Clin (Barc); 2019 May; 152(10):397-404. PubMed ID: 30612747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tumor lysis syndrome in intensive therapy: diagnostic and therapeutic encare].
    Burghi G; Berrutti D; Manzanares W
    Med Intensiva; 2011 Apr; 35(3):170-8. PubMed ID: 21112673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor lysis syndrome: new challenges and recent advances.
    Wilson FP; Berns JS
    Adv Chronic Kidney Dis; 2014 Jan; 21(1):18-26. PubMed ID: 24359983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hyperuricemia with rasburicase review.
    de Bont JM; Pieters R
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1431-40. PubMed ID: 15571272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of pediatric tumor lysis syndrome.
    Tazi I; Nafl H; Elhoudzi J; Mahmal L; Harif M
    Arab J Nephrol Transplant; 2011 Sep; 4(3):147-54. PubMed ID: 22026339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute renal failure in patients with tumour lysis sindrome].
    Poskurica M; Petrović D; Poskurica M
    Srp Arh Celok Lek; 2016; 144(3-4):232-9. PubMed ID: 27483573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of tumor lysis syndrome.
    Rampello E; Fricia T; Malaguarnera M
    Nat Clin Pract Oncol; 2006 Aug; 3(8):438-47. PubMed ID: 16894389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
    Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K
    J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention and Treatment of Tumor Lysis Syndrome in the Era of Onco-Nephrology Progress.
    Matuszkiewicz-Rowinska J; Malyszko J
    Kidney Blood Press Res; 2020; 45(5):645-660. PubMed ID: 32998135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor lysis syndrome.
    Jeha S
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):4-8. PubMed ID: 11694945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002.
    Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA
    Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing tumor lysis syndrome.
    Greguska C
    JAAPA; 2021 Jan; 34(1):10-13. PubMed ID: 33315730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Our experience with tumor lysis syndrome treatment.
    Sirelkhatim A; Sejnova D; Puskacova J; Subova Z; Kaiserova E
    Bratisl Lek Listy; 2008; 109(12):560-3. PubMed ID: 19348378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.